HCM
MRNA icon

Heathbridge Capital Management’s Moderna MRNA Stock Holding History

Heathbridge Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29,110
Closed -$3.01M – 31
2023
Q3 		$3.01M Sell
29,110
-300
-1% -$33.5K 1.38% 19
2023
Q2 		$3.57M Sell
29,410
-1,175
-4% -$157K 1.56% 19
2023
Q1 		$4.7M Sell
30,585
-1,850
-6% -$305K 1.98% 18
2022
Q4 		$5.83M Sell
32,435
-17,650
-35% -$2.89M 2.24% 19
2022
Q3 		$5.92M Sell
50,085
-215
-0.4% -$32.6K 2.68% 15
2022
Q2 		$7.18M Sell
50,300
-230
-0.5% -$32.9K 2.96% 14
2022
Q1 		$8.7M Sell
50,530
-23,750
-32% -$4M 2.77% 15
2021
Q4 		$18.9M Buy
74,280
+5,905
+9% +$1.73M 5.4% 8
2021
Q3 		$26.3M Sell
68,375
-52,425
-43% -$19.3M 7.9% 7
2021
Q2 		$28.4M Sell
120,800
-23,550
-16% -$4.21M 7.62% 9
2021
Q1 		$18.9M Buy
+144,350
New +$20.9M 5.19% 8

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Heathbridge Capital Management's MRNA Position: Q4 2023 in Review

Heathbridge Capital Management sold out of Moderna (MRNA) in Q4 2023, closing a stake of 29,110 shares — an estimated $3.01M sold.

Heathbridge Capital Management first reported a position in MRNA in Q1 2021 and held it in 11 quarters. The position peaked at $28.4M in Q2 2021. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Heathbridge Capital Management reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Heathbridge Capital Management sold 29,110 Moderna shares in Q4 2023, an estimated $3.01M.
  • Heathbridge Capital Management first reported a position in Moderna in Q1 2021 and held it in 11 quarters.
  • Heathbridge Capital Management's Moderna position peaked at $28.4M in Q2 2021.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Heathbridge Capital Management's 13F filing for Q4 2023, filed 15 Feb 2024.